drug
metaxalone
Marketedupdated 6mo agoby CorePharma LLC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying metaxalone
- phase4Effect of Metaxalone 640 mg (M640) on Driving, Cognition, and EEG Dynamics Compared to Tizanidine 8 mg in Adults
- phase4Testing Healthy Participants for Drowsiness After Single Dosing of Two Different Doses of Muscle Relaxer
- phase4Assess the Effect of Metaxalone 640 mg (M640) Compared to Tizanidine 8 mg on Truck Driving Ability and Cognition
- phase4Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.
- phase4Study to Assess Drowsiness, Cognition, Fall Risk After Metaxalone 640 mg and Metaxalone 800 mg
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 29, 2039
~12.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Jul 29, 2039formulationUS 11918559
- Feb 6, 2026method-of-use (U-915)US 7122566
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that